Last Updated: August 2, 2026

LUXIQ Drug Patent Profile

✉ Email this page to a colleague

When do Luxiq patents expire, and when can generic versions of Luxiq launch?

Luxiq is a drug marketed by Pharmobedient and is included in one NDA.

The generic ingredient in LUXIQ is betamethasone valerate. There are sixty-six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Luxiq

A generic version of LUXIQ was approved as betamethasone valerate by FOUGERA PHARMS INC on August 31^st, 1983.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for LUXIQ?
What are the global sales for LUXIQ?
What is Average Wholesale Price for LUXIQ?

Summary for LUXIQ

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for LUXIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUXIQ	Foam	betamethasone valerate	0.12%	020934	1	2007-08-10

US Patents and Regulatory Information for LUXIQ

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	LUXIQ	betamethasone valerate	AEROSOL, FOAM;TOPICAL	020934-001	Feb 28, 1999		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for LUXIQ

See the table below for patents covering LUXIQ around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Austria	253367		⤷ Start Trial
Australia	4885196		⤷ Start Trial
Australia	709320		⤷ Start Trial
Brazil	9607687		⤷ Start Trial
Canada	2214436	COMPOSITION PHARMACEUTIQUE CONTENANT UN CORTICOSTEROIDE (CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.